{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Cedars-Sinai
Cedars-Sinai
  • Sign In
  • Live Activities
  • Internal Series
  • On-Demand Activities
  • CE Planning Process
  • Calendar
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Use My Cedars Login
Login with my CloudCME™ account
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Forgot Your Password?

Login Tips: 
PLEASE CREATE AN ACCOUNT IF:

• You have never attended a Cedars-Sinai CE activity
• OR You are a NEW member of the Cedars-Sinai Medical Staff since August 2023

If you do NOT meet either of the criteria above, please DO NOT CREATE AN ACCOUNT:

• If you do not know which email address is used for your account, please contact the Cedars-Sinai Office of CME.
• Accounts for existing Cedars-Sinai Medical Staff (prior to August 2023) use the primary email on file with the Medical Staff Office.

For ALL USERS: If you do not have the password for your account, click the "Forgot Your Password?" link.

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • ATC
  • BSN
  • CCC-SLP
  • CCLS
  • CPhT
  • CRNA
  • CRT
  • DC
  • DDS
  • DMD
  • DNAP
  • DNP
  • DO
  • DPM
  • LCGC
  • LCSW
  • LVN
  • MBBCh
  • MBBS
  • MD
  • MD, PhD
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • NP
  • OT
  • Other
  • OTR/L
  • PA
  • PharmD
  • PhD
  • PsyD
  • PT
  • RD
  • RN
  • RN, BSN
  • RPh
  • RRT
  • RT
  • RVT
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

2025 Research Updates in Lymphoma


2025 Research Updates in Lymphoma Banner

  • Overview
  • Register
  • Faculty
  • Schedule
Add to Calendar 2025 Research Updates in Lymphoma 10/18/2025 7:30:00 AM 10/19/2025 3:00:00 PM America/Los_Angeles For More Details: https://cedars.cloud-cme.com/lymphomacme Description: This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, "How I Treat" sessions will address questions of sequencing therapies and patients selection. The scientific sessions will prese... Cedars-Sinai Pavilion Education Center false MM/DD/YYYY


Date & Location
Saturday, October 18, 2025, 7:30 AM - Sunday, October 19, 2025, 3:00 PM PT, Cedars-Sinai Pavilion Education Center, Los Angeles, CA

Target Audience
Specialties - Hematology, Imaging, Internal Medicine, Oncology, Pathology & Laboratory Medicine, Radiation Oncology, Radiology, Surgery
Professions - Nurse, Nurse (Advanced Practice NP CRNA CNM CNS), Other (non-physician), Physician, Physician Assistant, Researcher (non-physician), Researcher (physician)

Overview
This conference will provide a chance for Southern California lymphoma specialists and national experts to gather and discuss updates and advancements in lymphoma treatment and research. The clinical updates sessions will highlight newly approved therapies and those in the pipeline. Case based, "How I Treat" sessions will address questions of sequencing therapies and patients selection. The scientific sessions will present high impact basic science with high translational relevance, such as new biomarkers, therapeutic targets and novel cellular therapies.

Objectives
  1. Recognize the utility of molecular testing in the classification and treatment of lymphoma
  2. Identify current evidence based treatments for Hodgkin lymphoma, diffuse large B cell lymphoma, and peripheral T cell lymphoma
  3. Describe new treatments under development including bi specific antibodies and CART therapies
  4. Collaborate as an interprofessional healthcare team to evaluate the role of molecular testing in lymphoma classification, apply evidence based treatments for various lymphoma subtypes, and discuss emerging therapies such as bispecific antibodies and CAR T cell therapies to optimize patient care through shared knowledge and coordinated decision making

Registration

In-Person Fees
In-Person: Healthcare Professional Fee - $0.00
In-Person: Industry Attendee (No Exhibit Booth) - $550.00

Virtual Fees
Virtual: Healthcare Professional Fee - $0.00
Virtual: Industry Attendee (No Exhibit Booth) - $550.00


Accreditation

In support of improving patient care, Cedars-Sinai is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA Credit Designation Statement
Cedars-Sinai designates this Live Activity for a maximum of 10.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician AMA Attendance
Attendance credit will be provided to other healthcare professionals upon the fulfillment of attendance requirements. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.  

ANCC Credit for Nurses:  This activity is approved for 10.00 ANCC contact hours.

Interprofessional Continuing Education: This activity was planned by and for the healthcare team and learners will receive 10.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.


Credits
AMA PRA Category 1 Credit(s)™ (MD, DO) (10.00 hours), ANCC (10.00 hours), IPCE (10.00 hours), Non-Physician AMA Attendance (10.00 hours)


Keywords: LIVEAMAANCCIPCEHybrid (In-person and Virtual)



Mitigation of Relevant Financial Relationships


Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.



Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Faculty Photos
Hitomi Hosoya, MD, PhD
Cedars-Sinai
Course Director, Faculty
Nothing to disclose
Faculty Photos
Akil Merchant, MD
Cedars-Sinai
Course Director, Faculty
Advisor-Novartis AG|Advisor-Pfizer, Inc.|Advisor-Morphosys|Consultant-Genmab|Consultant-Abbvie|Consultant-Bristol-Myers Squibb
Faculty Photos
Elizabeth Brem, MD
UCI School of Medicine
Faculty
Consultant-BeOne|Speaker-AstraZeneca|Advisor-AstraZeneca|Advisor-Genentech, Inc.|Advisor-Regeneron|Advisor-ADC Therapeutics|Advisor-Caribou Biosciences (Relationship has ended)|Advisor-Posieda (Relationship has ended)|Advisor-Incyte (Relationship has ended)|Advisor-Bristol-Myers Squibb (Relationship has ended)|Speaker-Bristol-Myers Squibb|Speaker-AbbVie, Genmab|PrincipalNamedInvestigator-Regeneron
Faculty Photos
Yvonne Chen, PhD
Microbiology, Immunology & Molecular Genetics, UCLA
Faculty
StockPrivate-ImmPACT Bio (Relationship has ended)|StockPrivate-Catamaran Bio (Relationship has ended)|StockPrivate-Notch Therapeutics (Relationship has ended)|StockPrivate-Pluto Immunotherapeutics|StockPrivate-Sonoma Biotherapeutics|StockPrivate-Waypoint Bio|Stock Options or Shareholder-Prime Medicine|Consultant-Novartis AG (Relationship has ended)|StockPrivate-AffyImmune (Relationship has ended)|StockPrivate-Lyell Immunopharma|StockPrivate-Harton
Faculty Photos
Anthony R Colombo, PhD
USC
Faculty
Nothing to disclose
Faculty Photos
Sean R Corcoran , MD, PhD
Cedars-Sinai
Faculty
Stock Options or Shareholder-CRISPR Therapeutics
Faculty Photos
Justin Darrah, MD
Cedars-Sinai
Faculty
Advisor-Genmab (Relationship has ended)
Michael B. Elowitz, PhD
Caltech
Faculty
Speaker-Kyowa Kirin (Relationship has ended)|Other: Co-Founder and Scientific Advisor-Plasmidsaurus|Advisor-TeraCyte|Advisor-Spatial Genomics|Other: Co-Founder and Scientific Advisor-Asymptote Genetic Medicines|Other: Co-Founder and Scientific Advisor-TCGFB
Faculty Photos
Juliane Gust, MD, PhD
Dr. (Ms.)
Faculty
Nothing to disclose
Faculty Photos
Sarah Larson, MD
UCLA Health
Faculty
PrincipalNamedInvestigator-Bristol-Myers Squibb|PrincipalNamedInvestigator-Kite|PrincipalNamedInvestigator-Johnson and Johnson|PrincipalNamedInvestigator-Lyell|PrincipalNamedInvestigator-Bioline (Relationship has ended)|PrincipalNamedInvestigator-Pfizer, Inc.|PrincipalNamedInvestigator-Regeneron|Speaker-Regeneron|Consultant-Johnson and Johnson
Ann Liu, Other
Faculty
Royalties or Patent Beneficiary-Port Therapeutics
Faculty Photos
Joseph C. Lownik, MD
Cedars-Sinai
Faculty
Nothing to disclose
Faculty Photos
Matthew G. Mei, MD
City of Hope
Faculty
Consultant-SeaGen (Relationship has ended)|Consultant-ADC Therapeutics (Relationship has ended)|Speaker-SeaGen (Relationship has ended)|Consultant-Synthekine (Relationship has ended)
Caspian Oliai, MD
Faculty
Nothing to disclose
Faculty Photos
David R. Oveisi, MD
Cedars Sinai Medical Center
Faculty
Consultant-Johnson and Johnson (Relationship has ended)|Speaker-Johnson and Johnson (Relationship has ended)|Advisor-Pfizer, Inc.|Consultant-Bristol-Myers Squibb|PrincipalNamedInvestigator-Johnson and Johnson
Giri Ramsingh , MD
Obsidian Therapeutics
Faculty
Employment-Obisidian Therapeutics
Faculty Photos
Lisa M Rimsza, MD
The University of Arizona
Faculty
Speaker-Roche
David Russler-Germain, MD, PhD
WashU Medicine
Faculty
Advisor-Genentech, Inc. (Relationship has ended)|Consultant-Regeneron|Consultant-Tempus|Advisor-Ipsen (Relationship has ended)|Consultant-AbbVie (Relationship has ended)
Parag Sanghvi, MD
UC San Diego School of Medicine
Faculty
Nothing to disclose
Faculty Photos
Joe Schroers-Martin, MD
Stanford Medicine
Faculty
Consultant-Pierre-Fabre|Advisor-Incyte (Relationship has ended)|Consultant-Navya
Faculty Photos
Hrishikesh Srinagesh, MD
Stanford Medicine
Faculty
Other: Honoraria-Sobi (Relationship has ended)|Other: Honoraria-Takeda (Relationship has ended)
Faculty Photos
Brian Sworder, MD, PhD
University of California, Irvine
Faculty
Consultant-Foresight Diagnostics|Stock Options or Shareholder-Cargo Therapeutics|Stock Options or Shareholder-Allogene Therapeutics|Consultant-ADC Therapeutics
Kevin Tang, MD
Cedars Sinai Medical Center
Faculty
Nothing to disclose
Wen-Kai Weng, MD, PhD
Stanford Medicine
Faculty
Nothing to disclose
Mina Xu, MD
Yale University School of Medicine
Faculty
Nothing to disclose
Alyssa Maskell, MSN
Cedars Sinai
Planner
Nothing to disclose

Saturday, October 18, 2025
Registration Check In and Exhibits
7:30AM - 8:00AM

Welcome and Introduction
8:00AM - 8:10AM
 
Session 1: Hot Topics in Clinical Lymphoma – Part I

Session Chair: Sarah Larson, MD
Frontline Therapy for Advanced Hodgkin Lymphoma: ECHELON-1, SWOG S1826, and GHSG HD21 (BrECADD) Updates
8:10AM - 8:35AM
Joe Schroers-Martin, MD

Novel Approaches in First-Line DLBCL: Beyond R-CHOP POLARIX, Zilovertamab Vedotin + R-CHP Updates
8:35AM - 9:00AM
Matthew G. Mei, MD

Dual Targeting CART for Lymphoma
9:00AM - 9:25AM
Sarah Larson, MD

Break and Exhibits
9:25AM - 9:45AM

 
Session 2: Hot Topics in Clinical Lymphoma – Part II

Session Chair: Justin Darrah
Bispecific Antibodies in DLBCL and Follicular Lymphoma: Current Successes and Future Combinations
9:45AM - 10:10AM
Justin Darrah, MD

T-Cell Lymphoma
10:10AM - 10:35AM
Wen-Kai Weng, MD, PhD

Role of Radiation Therapy in Lymphoma
10:35AM - 11:00AM
Parag Sanghvi, MD

 
Lightning Round

Lightning Round: Open Clinical Trials for Lymphoma in LA area (90 sec per trial)
11:00AM - 11:30AM

 
Lunch and Networking

Lunch and Exhibits
11:30AM - 12:15PM

 
Session 3: Keynote & Basic Science Insights

Session Chair: Akil Merchant, MD
KEYNOTE ADDRESS: Spatial Profiling in Lymphoma: Unveiling the Tumor Microenvironment and Cellular Interactions
12:15PM - 1:00PM
Mina Xu, MD

Microenvironment in Non-Hodgkin Lymphoma
1:00PM - 1:20PM
Anthony R Colombo, PhD

Hidden Opponents: The DLBCL Microenvironment
1:20PM - 1:40PM
David Russler-Germain, MD, PhD

Metabolic Profiling and Modulation of the Lymphoma Microenvironment
1:40PM - 2:00PM
Akil Merchant, MD

Break and Exhibits
2:00PM - 2:20PM
 
Session 4: Next Generation Diagnostics and Biomarkers

Session Chair: Joseph C. Lownik, MD
Biomarkers for Clinical Stratification in Lymphoma
2:20PM - 2:50PM
Lisa M Rimsza, MD

Developing an Automated Multiplex IF for Diagnostic/Biomarker Use in Lymphoma
2:50PM - 3:10PM
Joseph C. Lownik, MD

Role of ct DNA in Lymphoma
3:10PM - 3:30PM
Brian Sworder, MD, PhD
Geriatric Assessment of Patients with Lymphoma: Clinical Trial and Routine Practice
3:30PM - 3:50PM
Elizabeth Brem, MD

Molecular Determinants of Sensitivity to Polatuzmab
3:50PM - 4:10PM
Sean R Corcoran , MD, PhD

Adjourn
4:10PM - 4:15PM

 
Networking Reception

Networking Reception
4:15PM - 5:30PM

Sunday, October 19, 2025
Registration Check In and Exhibits
7:30AM - 8:00AM

 
Session 1: CAR-T Cell Therapy: Managing Complex Toxicities

Session Chair: Hitomi Hosoya, MD, PhD
Mechanisms of Neurotoxicity with IEC and Bispecific Therapies
8:00AM - 8:20AM
Juliane Gust, MD, PhD

IEC-HS: Diagnosis (ASTCT Criteria), Pathophysiology, and Management
8:20AM - 8:40AM
Hrishikesh Srinagesh, MD
Prophylactic Strategies for CAR-T Toxicities: Role of Early Steroids, Anakinra, and Other Novel Approaches
8:40AM - 9:00AM
Caspian Oliai, MD

Secondary and T-cell Malignancies after CART
9:00AM - 9:20AM
Hitomi Hosoya, MD, PhD

Break and Exhibits
9:20AM - 9:35AM
 
Session 2: Clinical Debate--What is the Optimal Bridging Strategy for CAR-T Therapy

Session Chair: Justin Darrah, MD
Intro: Why bridging?
9:35AM - 9:40AM
Justin Darrah, MD

Role of Bispecifics as Bridging
9:40AM - 9:50AM
Sarah Larson, MD

Radiation as Bridging
9:50AM - 10:00AM
Parag Sanghvi, MD

Optimal Chemotherapy for Bridging
10:00AM - 10:10AM
David R. Oveisi, MD
Debate and Discussion
10:10AM - 10:35AM

 
Session 3: Next Generation Cellular Therapies for Lymphoma and Beyond

Session Chair: Yvonne Chen, PhD
Novel CART for Solid Tumors
10:35AM - 10:55AM
Yvonne Chen, PhD

Innovations in TIL Therapy
10:55AM - 11:15AM
Giri Ramsingh , MD

Macrophage Based Therapies
11:15AM - 11:35AM
Ann Liu, Other

Engineered Protein Circuits for Cancer Therapy
11:35AM - 11:55AM
Michael B. Elowitz, PhD

Closing and Boxed Lunch
11:55AM - 12:00PM


CE Disclosure Form  | CE Application  | Privacy  |  Cedars-Sinai CME Homepage

Contact Us: [email protected]

        

© 2025 Cedars-Sinai Health Sciences University. All Rights Reserved. A 501(c)(3) non-profit organization.